UBS AM’s Neumora Therapeutics NMRA Stock Holding History
Bought
Maintained
Sold
Other funds holding NMRA
SL
UBS AM's NMRA Position: Q3 2026 in Review
UBS AM opened a new position in Neumora Therapeutics (NMRA) in Q3 2026: 679 shares worth $405. The stake represents ﹤0.01% of the portfolio and ranks #4186 among its holdings. This is a return to the name: UBS AM previously reported a position in NMRA as recently as Q4 2024.
UBS AM first reported a position in NMRA in Q4 2024 and has held it in 2 quarters since. The position peaked at $770K in Q4 2024. 100 funds tracked by Wall St. Rank hold NMRA as of Q3 2026.
- UBS AM held 679 shares of Neumora Therapeutics worth $405 as of Q3 2026.
- Neumora Therapeutics was a new UBS AM position in Q3 2026.
- Neumora Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q3 2026, its #4186 holding.
- UBS AM first reported a position in Neumora Therapeutics in Q4 2024 and has held it in 2 quarters since.
- UBS AM's Neumora Therapeutics position peaked at $770K in Q4 2024.
- 100 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q3 2026.
Based on UBS AM's 13F filing for Q3 2026, filed 16 Nov 2026.